Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor Eamon Edward Keenan

Clinical Professor (Public Health & Primary Care)
      
Profile Photo

Professor Eamon Edward Keenan

Clinical Professor (Public Health & Primary Care)

 


Project Title
 Prescription drugs with potential for misuse: A multi-indicator analysis of supply, patterns of use and the associated health burden in Ireland over the past ten years
From
20/12/21
To
31/12/23
Summary
Prescription drugs are often strong medications, which is why they require a prescription and are not available over the counter. There is increasing concern about the misuse of certain prescription drugs, for example opioids (prescribed for pain relief), and benzodiazepines, a group of medicines often used in the shortterm to treat anxiety or sleeping problems. Misuse of prescription drugs generally refers to taking a prescribed drug in a way other than how it was prescribed, for example taking someone else's medication or taking more than the prescribed dose to create a feeling of euphoria or to get "high". It also refers to taking illegally sourced prescription drugs, which is high risk as the drugs may be fake and/or contain harmful substances. The Health Research Board and the Department of Health in Ireland have identified the misuse of prescription drugs as a research priority in Ireland. As there is no single source of information that fully describes the situation in Ireland, we are proposing to examine many different Irish data sources to provide a detailed analysis of the supply, patterns of use and harms associated with prescription drugs with potential for misuse (PDPM).
Funding Agency
HRB SDAP
Programme
Secondary Data Analysis Project
Project Type
Data linkage Project
Person Months
2
Project Title
 Exploring the risk factors and consequences of cannabis use in adolescence using population-based data: the "CANNARISK" study
From
01/10/22
To
30/09/26
Summary
Over the past decade there has been an increase in the number of adolescents using cannabis worldwide. This is concerning because cannabis is increasing in strength with more serious long term effects on health such as psychosis and depression. The adverse effects of using cannabis are particularly pronounced in those who start to use cannabis in adolescence. However despite the evidence for harmful effects, young people are less likely likely to view cannabis as a harmful substance. In this project we aim to investigate two key issues in relation to cannabis use in youth. Firstly we will examine what factors increase the chances of a young person beginning to use cannabis. We will also examine what factors influence a young person not to use cannabis. Secondly we will investigate what effect early use of cannabis has on the structure of the brain and on cognition.
Funding Agency
HRB
Programme
Investigator Led Projects
Project Type
Investigative
Person Months
2
Project Title
 Sustaining increased and improved access to opioid substitution treatment (OST) in Ireland: a mixed-methods study to evaluate the impact of national contingency OST guidelines on process and client outcomes, and identify quality indicators for the continued and safe delivery of OST throughout and beyond COVID-19.
From
Nov 2020
To
Nov 2021
Summary
While opioid substitution treatment (OST) is the most effective treatment for opioid dependence, it is heavily dependent on regular face-to-face health care delivery placing both clients and treatment providers at risk of COVID-19. Policies were rapidly changed with the introduction of Page 18 of 44 national contingency guidelines by the HSE National Social Inclusion Office, where Addiction services are coordinated, beginning in March 2020 to ensure rapid and uninterrupted access to OST while balancing efforts to mitigate COVID-19 risk. The Programme for Government 2020 states they will retain many of the measures introduced during COVID-19 to reduce waiting times in accessing treatment services and reduce overdose mortality. It is therefore essential to examine the impacts, benefits and unintended consequences of the special measures introduced during COVID-19 at a national level, thus informing which measures can and should be sustained throughout and beyond COVID-19 to support effective, safe and patient-centred care promoting the health and welling being of all people with opioid dependence. The aim of this project is to evaluate the impact of the national contingency guidelines, developed in response to COVID-19, on the quality of OST care delivered in Ireland, and to identify priorities for quality and safety improvements which will inform clinical decision making throughout and beyond the pandemic. This will be achieved through evaluating the impact of contingency guidelines on numbers entering OST, numbers on waiting list, waiting times, patient dropout and mortality using an interrupted time series analysis of data from the national OST treatment register (Central Treatment List) from June 2019 to December 2020, alongside a Delphi consensus study of quality indicators for the safe delivery of OST in Ireland throughout and beyond COVID-19. Evidence generated from these studies will inform national policy decisions in relation to improving quality of care in OST.This offers a real opportunity for changes identified within the research and recommendations arising from the research to be translated into meaningful actions for Addiction services in Ireland and possibly Europe in the coming years.
Funding Agency
RCQPS
Programme
Covid 19
Project Type
Mixed Methods Study
Person Months
1
Project Title
 Methadone substitution treatment: mortality and progression pathways
From
15/05/17
To
14/05/21
Summary
Despite evidence supporting methadone substitution treatment (MST), methadone itself has been associated with drug-related deaths. A recent external review of methadone services in Ireland concluded that Ireland is currently lacking a systematic approach of data linkage which is essential to determine the quality of care delivered to drug users in treatment, particularly in relation to mortality. The National Drug Strategy 2009-2016 also concluded that clinical research is underdeveloped. Understanding progression pathways in treatment and qualitative research regarding service users' experiences were identified as research priorities. The proposed study aims to inform evidence-based treatment guidelines to reduce the risk of mortality associated with MST and to provide a better understanding of progression pathways within the addiction services. Using a sequential mixed methods study design, the project will involve a record linkage cohort study of approximately 3,000 patients attending specialist addiction outpatient services in Dublin South West between 2010 and 2015. The primary objectives of this cohort study are: (1) to investigate the extent to which the impact of MST on mortality (all cause and drug-related) is influenced by modifiable treatment related factors such as treatment modality, dose, treatment duration, co-prescriptions including benzodiazepines and dispensing arrangements including supervised methadone consumption; (2) to identify determinants of time to progression to treatment in primary care or detoxification; and (3) determinants of time to discontinuation in MST. This will be combined with in-depth qualitative interviews with 40 drug users in relation to their treatment pathways or journey to-date, experiences of non-fatal overdose, poly-drug use and supervised methadone consumption. Evidence generated from this study will inform both national and international policy decisions in relation to improving quality of care in MST and reducing mortality. This study will also inform evidence based initiatives around progression pathways, taking the service users perspective into account. The overall aim of this project is to generate evidence based standards for the quality of clinical care in methadone substitution treatment (MST) in addiction services, which will inform future policy decisions on initiatives to reduce the risk of mortality associated with MST and to provide a better understanding of progression pathways within the addiction services. This will be achieved through a sequential mixed method study design which will involve a record-linkage study of approximately 3,000 patients attending specialist addiction outpatient services in Dublin South West, followed by a qualitative study of drug users' experiences of treatment and non-fatal overdose.
Funding Agency
HRB
Programme
Health Research Awards - Population Health Research
Project Type
Mixed Methods Study
Person Months
4
Project Title
 Peer Led Addiction Recovery (Predictor) Programme
From
November 2020
To
Delayed due to Covid
Summary
Recovery coaching is an innovative psychosocial form of strengths-based support for individuals in addiction. Recovery Coaches are experts-by-experience. They support any positive change, helping individuals as they enter and exit treatment to avoid relapse, build community support, formulate goals regarding work, enter education, and build and sustain relationships (i.e. developing recovery capital). There is an emerging body of research primarily in Australia, the US and the UK showing support for recovery coaching. While the role of the Recovery Coach is relatively new in addiction recovery, peer support has been hugely successful in the mental health field and, more recently, homeless services. Developing an intervention that will assist individuals to build resources and reduce the potential for relapse will be hugely beneficial at an individual, community and health service.
Funding Agency
Cork Local Drug and Alcohol Task Force
Programme
Once off funding
Project Type
Pilot version

Details Date
National Clinical Lead for HSE Addiction Services. Views sought and asked to comment publicly on a range of issues associated with drug and alcohol use in Ireland. Regular advice to Government and responding to Parliamentary Questions and Representations for the Minister on drug related issues 2016
Chair of HSE National Red Alert Response Group established in the wake of the Emergence of the synthetic opioids, nitazenes, on the Irish drug market 09.12.2023
HSE Representative on the National Oversight Committee for National Drug and Alcohol Strategy 2017
Management Board, European Union Drugs Agency (EUDA) determining policy and direction for drug services in Europe through advice to European Commission 2019
Chair of HSE Codeine Working Group examining potential impact of legislative changes to codeine scheduling 2023
Irish representative on EU National Drug Coordinators Group to disseminate knowledge and best practice within member EU states 2019
HSE representative on the Ministerial Rapid Response Group on Drug Use in Higher Education Institutions 2019
Member of Health Committee of Irish Medical Council Provides support to Doctors experiencing Health difficulties 2013
HSE Primary Care representative on Cross Departmental National Steering Group for 'Connecting for Life', Ireland's National strategy to reduce suicide and self harm in society 2016
HSE representative on High Level Task Force on mental health and addiction challenges of persons interacting with the criminal justice sector 2021
Medical Council Stakeholder Group on overprescribing of Benzodiazepines and other Drugs Will inform and influence National Policy 2019
Member of Project Team on Drug Use in Higher Education in Ireland (DUHEI) survey project 2019
Member of HSE Hepatitis C Programme Advisory Group providing roll out of HCV vaccination programme to vulnerable groups in society 2016
Chair of Emerging Drug Trends Working Group convened to progress Specific actions within the National Drug and Alcohol Strategy 2019
Chair of Registration Committee of College of Psychiatrists of Ireland 2014
Member of College of Psychiatrists Council Sub Committee on Policy and Strategy. Rep from Addiction Faculty 2021
Chair of HSE Working Group to advise on establishment of Medically Supervised Injection Facility. Included Service User Representation 2016
Chair of Irish Psychiatric Training Committee (Eastern Region) 2004
Chair of Treatment/Rehabilitation Committee of the National Advisory Committee on Drugs (NACD) Involved commissioning of research including ROSIE study 2004
Member of the Forum of Irish Postgraduate Medical Training Bodies - College of Psychiatrists Representative 2014
Details Date From Date To
Member of College of Psychiatrists of Ireland 2008
Member of Royal College of Psychiatrists 1991 2008
Medico-Legal Society of Ireland 2024
Louise Durand; Ella Arensman; Paul Corcoran; Caroline Daly; Kathleen Bennett; Suzi Lyons; Eamon Keenan; Gráinne Cousins, Harms associated with prescription drug misuse in Ireland: a national observational study of trends in treatment demand, non-fatal intentional drug overdoses and drug related deaths 2010 to 2020, Drug and Alcohol Dependence, 2025, Journal Article, PUBLISHED  DOI
Killeen N, Lakes, R, Webster M, Killoran S, McNamara S, Kavanagh P, Eagleton M, McCormack S, Micheau E, Moughty, A, O'Donnell M, O'Reilly C, Doyle G, O'Rourke S, Downing S, Flynn C, Keenan e, The emergence of nitazenes on the Irish heroin market and national preparation for possible future outbreaks, Addiction, 119, 2024, p1657 - 1658, Journal Article, PUBLISHED  DOI
E Keenan, C Kelleher, S Lyons, N Sweeney, Etilzolam and Irish Drug Poisoning Deaths, Irish Journal of Psychological Medicine, 2024, Journal Article, PUBLISHED  DOI
Durand L, O'Kane A, Stokes S, Bennett KE, Keenan E, Cousins G, Trends in polysubstance use among patients in methadone maintenance treatment in Ireland: Evidence from urine drug testing 2010-2020, Journal of Substance Use and Addiction Treatment, 2024, Notes: [https://doi.org/10.1016/j.josat.2024.209507], Journal Article, PUBLISHED  DOI
Evans DS, Harnedy N, Keenan E, Community Pharmacy Needle Exchange Programme. Wwhat can analysis of the data tell us about the changing drug market in Ireland, Int J Environ Res Public Health, 21, (3), 2024, Journal Article, PUBLISHED  DOI
Killeen N, McNamara S, Keenan E, K culture', ketamine's prominent yet overlooked role on the Irish drug scene and implications for health, Irish Journal of Medical Science, 2023, Journal Article, PUBLISHED  DOI
Gráinne Cousins, Louise Durand, Aoife O'Kane, Julie Tierney, Richard Maguire, Siobhán Stokes, Deirdre O'Reilly, Ella Arensman, Kathleen E Bennett, María Otero Vázquez, Paul Corcoran, Suzi Lyons, Yvonne Kavanagh, Eamon Keenan, Prescription drugs with potential for misuse: protocol for a multi-indicator analysis of supply, detection and the associated health burden in Ireland between 2010 and 2020, BMJ Open, 2023, p1 - 9, Journal Article, PUBLISHED  DOI
Durand L; Keenan E; O'Reilly D; Bennett K; O'Hara A; Cousins G, Prescription drugs with potential for misuse in Irish prisons: analysis of national prison prescribing trends, by gender and history of opioid use disorder, 2012 to 2020, BMC Psychiatry, 2023, Journal Article, PUBLISHED  DOI
Smyth BP, Davey A, Keenan E, Deterence Effect of Penalties on Adolescent Cannabis Use, Irish Journal of Psychological Medicine, 2023, Journal Article, PUBLISHED  DOI
Durand L, Boland F, Harnedy N, Delargy Í, Scully M, Bourke M, Ebbitt W, Vázquez MO, Keenan E, Cousins G, Impact of changes to the delivery of opioid agonist treatment, introduced during the COVID-19 pandemic, on treatment access and dropout in Ireland: An interrupted time series analysis, Journal of Substance Use Addiction Treatment, 2023, Journal Article, PUBLISHED  DOI
  

Page 1 of 11
Eamon Keenan, The Emerging Situation with Nitazenes in Ireland, Lisbon Addictions 2024, Lisbon, Portugal, 25th October 2024, 2024, Invited Talk, PRESENTED
Eamon Keenan, 'Over the counter medications' Dependencies and developments, Medico Legal Society of Ireland 68th Session, Dublin, 22.03.2024, 2024, Medico Legal Society of Ireland, Invited Talk, PRESENTED
Eamon Keenan, Emerging Drug Trends, INMO CPC Section Annual Conference, Richmond Hospital Conference Centre, 08/10/24, 2024, INMO, Invited Talk, PRESENTED
D Evans, E Keenan, Opioid Agonist Treatment for people experiencing homelessness in Ireland: Key patterns and trends 2014 - 2023, HSE National Social Inclusion Office, December, 2024, Report, PUBLISHED
Eamon Keenan, Health Service Provision, Citizens Assembly on Drug Use, The Grand Hotel, Malahide, Dublin, 24th June , 2023, Government of Ireland, Invited Talk, PRESENTED
Eamon Keenan, HSE Clinical Programme on Dual Diagnosis in Changing Drugs Landscape - Everywhere, Everything, Everyone, Launch of Clinical Programme on Dual Diagnosis, Morrison's Hotel, Dublin, 23rd May, 2023, HSE Mental Health Division, Invited Talk, PRESENTED
Eamon Keenan, HSE Perspective on Drug Use in Ireland, Citizens Assembly on Drug Use, The Grand Hotel, Malahide, Dublin, 16th April, 2023, Government of Ireland, Invited Talk, PRESENTED
David Evans, Eamon Keenan, Drug Treatment in Ireland: Key Patterns and Trends: 2014 - 2021, HSE, Ireland, HSE National Social Inclusion Office, June, 2023, Notes: [Merging two separate statutory databases to identify a more accurate figure of people in receipt of drug treatment in Ireland than had previously been recorded], Report, PUBLISHED
Eamon Keenan, Irelands Experience & Progression on the Provision of Naloxone, 65th Commission on Narcotic Drugs organised by the Netherlands - Side event on Prevention of Overdoses and Drug Related Deaths, Netherlands (Virtual), 15th March , 2022, UNODC, Invited Talk, PRESENTED
Eamon Keenan, Emerging Drug Trends and their impact on Mental Health Comorbidities, Dr Michal Kelleher Memorial Lecture, Virtual webinar, 14th October, 2022, National Suicide Research Foundation, Invited Talk, PRESENTED

  


Page 1 of 4
Award Date
Senior Registrar Prize in Psychiatry, RAMI 1994
Poster Prize winner at 2019 College of Psychiatrists Spring Conference 2019
Poster Prize winner 2018 Royal College Psychiatry, Faculty of Addictions Annual Conference 2018